Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Cerus Corporation is a biomedical products company focused on enhancing blood safety through its proprietary INTERCEPT Blood System technology. This system is designed to reduce blood-borne pathogens in donated blood components, including platelets, plasma, and red blood cells, for transfusion. Cerus markets its INTERCEPT systems globally through direct sales and distributors, positioning itself as a leader in pathogen reduction for blood products.
AI-generated summary. Not investment advice.